Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575618 | 0.93 | MTNR1A (0.36) | AAK1PRMT5WDR77STING1DGAT1 | |
| SCHEMBL23590154 | 0.87 | AAK1 (0.33) | AAK1PRMT5WDR77 | |
| SCHEMBL19747751 | 0.85 | CD274 (0.43) | DGAT1CD274CSF1R | |
| SCHEMBL23575590 | 0.84 | USP30 (0.38) | AAK1PRMT5WDR77STING1DGAT1 | |
| SCHEMBL23575623 | 0.81 | AAK1 (0.40) | AAK1PRMT5WDR77STING1DGAT1 | |
| SCHEMBL23575722 | 0.80 | AAK1 (0.38) | AAK1PRMT5WDR77STING1DGAT1 | |
| SCHEMBL26354105 | 0.80 | CD274 (0.39) | STING1MTNR1AMTNR1BSIGMAR1CD274 | |
| SCHEMBL23575474 | 0.79 | AAK1 (0.39) | AAK1PRMT5WDR77STING1DGAT1 | |
| SCHEMBL21227733 | 0.78 | MTNR1A (0.43) | STING1MTNR1AMTNR1BSIGMAR1CD274 | |
| SCHEMBL23629064 | 0.77 | LIPG (0.34) | DGAT1NR1I2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-3474900-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223452-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BRD9, BRWD1, BRD1 | AAK1 1716/4885PRMT5 1484/4885WDR77 263/4885 |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | AAK1 1473/4885PRMT5 2344/4885WDR77 110/4885 |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | AAK1 1473/4885PRMT5 2344/4885WDR77 110/4885 |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | AAK1 2545/4885PRMT5 2377/4885WDR77 64/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | AAK1 2893/4885PRMT5 2301/4885WDR77 563/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | AAK1 2893/4885PRMT5 2301/4885WDR77 563/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | AAK1 1473/4885PRMT5 2344/4885WDR77 110/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | AAK1 1473/4885PRMT5 2344/4885WDR77 110/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | AAK1 1473/4885PRMT5 2344/4885WDR77 110/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | AAK1 1473/4885PRMT5 2344/4885WDR77 110/4885 |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | BRD9, BRWD1, BRD1 | AAK1 1716/4885PRMT5 1484/4885WDR77 263/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | AAK1 1458/4885PRMT5 2374/4885WDR77 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.